FlandersBio on Twitter

Follow us on Twitter

Archive for September 2010 - News

Archive for September 2010 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Movetis wins two out of three categories at the PharmaVentures European Deals 2010 Awards

30.09.2010

Movetis NV (MOVE), the European gastrointestinal (GI) speciality pharmaceutical company, announces today that it has won the European Financing Deal of the Year and the European M&A Deal of the Year at the PharmaVentures European Deals 2010 Awards. The awards recognise Movetis’ successful IPO on Euronext Brussels in December 2009, as well as the recent public tender offer by Shire on all outstanding shares and warrants of Movetis. These prestigious awards were presented yesterday night at the Sachs Associates 10th Annual Biotech in Europe Investor Forum in Zurich. read more

ThromboGenics Signs Deal with MSD for Long-Term Commercial Supply of Microplasmin

30.09.2010

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that it has signed a 10-year supply agreement with MSD Biologics (UK) Ltd, part of the Merck BioManufacturing Network, for the production of microplasmin. ThromboGenics anticipates that this deal will meet its long-term commercial needs for bulk drug substance of this novel therapeutic agent. read more

arGEN-X awarded €1.5 million iwt grant to accelerate pre-clinical antibody development

28.09.2010

arGEN-X BV, a biopharmaceutical company focused on the discovery and development of therapeutic human antibodies (mAbs), today announced that it has received a €1.5 million grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT). This grant will be used to accelerate pre-clinical development of the lead program, ARGX-109 and two further therapeutic mAb programs. All three mAb candidates originated from arGEN-X’s proprietary SIMPLE Antibody™ platform and are being developed by the Company to target the inflammation/oncology space. read more

Galapagos starts Phase II clinical trial in rheumatoid arthritis patients

28.09.2010

Galapagos NV (Euronext: GLPG) announced today that it has started a Phase II clinical study for the Company’s flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis (RA). In this clinical trial, the safety and efficacy of this novel candidate drug will be tested in RA patients. Galapagos plans to announce interim results by the middle of next year and complete the trial by the end of 2011. read more

OncoMethylome Sciences Reinforces U.S. Presence with Key Executive Appointments

28.09.2010

OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) today announced the appointments of Dr. Melissa A. Thompson as Vice President Regulatory Affairs and Quality Assurance, and of Mr. Christopher (Chris) Thibodeau as Vice President Commercial Operations. read more

Janssen and EFSD will jointly fund research into the kidney’s role in diabetes

27.09.2010

Janssen and the European Foundation for the Study of Diabetes (EFSD) announced that the two organisations will jointly contribute up to a €500,000 pool to fund a three-year research programme into the role of the kidney in type 2 diabetes mellitus. EFSD is the research arm of the European Association for the Study of Diabetes (EASD). read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print